International Journal of Medical Laboratory Research (IJMLR)

INCIDENCE OF NAUSEA AND VOMITING IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY OR RADIOTHERAPY: OBSERVATIONS FROM SUPER-SPECIALITY HOSPITAL

 

Suresh Rao, Krishnaprasad, Sanath Kumar Hegde, Rosmy Jimmy, Soniya Abraham , Princy L Palattyb, Manjeshwar Shrinath Baliga*

 

ABSTRACT:BACKGROUND: Nausea and vomiting is a debilitating side effect in the treatment of cancer with chemotherapy and radiotherapy. At times this also affects the planned treatment schedule and the outcome. The present study was conducted to assess the incidence of acute nausea and vomiting in cancer patients undergoing chemotherapy or radiotherapy METHODS: This was a prospective study and was carried out in a superspeciality cancer hospital from June to July 2013. The incidence of nausea and vomiting were documented in 93 cancer patients requiring curative chemotherapy or radiotherapy after a week of treatment initiation.RESULTS: Majority of the patients were males, between the age group of 51 to 60 years, afflicted by cancers in the head and neck region and undergoing curative treatment. Diabetes was the most common co morbidity. The results of the study indicated that patients having co morbidities; undergoing chemotherapy or chemoradiotherapy were having more severe incidence of nausea and vomiting. From a gender perspective, females undergoing treatment were having more nausea and vomiting. CONCLUSIONS: These results indicate that in spite of adhering to the stipulated anti-emesis guidelines, the chemotherapy and chemo-irradiation-induced nausea and vomiting is a problem and needs careful monitoring. 

​

KEY WORDS: Nausea and vomiting, cisplatin, chemotherapy or chemoradiotherapy

​

REFERENCES:

1. Antonarakis ES, Hain RDW. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and practice. Arch Dis Child. 2004; 89:877-880.

2. Ibrahim NAE. Nausea and Vomiting in Cancer Patients: Topic Review. Ibrahim, JPalliat Care Med 2015, 5:1 http://dx.doi.org/10.4172/21657386.1000I203

3. Gozzo TO; de Souza SG, Moysés AMB, Panobianco MS, Almeida AM. Incidence and management of chemotherapy-induced nausea and vomiting in women with breast cancer. Rev Gaúcha Enferm. 2014; 35(3):117-123

4. Foubert J, Vaessen G. Nausea: the neglected symptom? Eur J Oncol Nurs 2005; 9(1): 21-32.

5. Börjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G. Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manage. 2002; 24(3):345-58.

6. Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013; 104:711-7.

7. Lai-Tiong F. Chemotherapy-Induced Nausea and Vomiting: An Oncology-Day Unit Experience. J Integr Oncol 2016, 5:1 http://dx.doi.org/10.4172/2329-6771.1000158

8. Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer. 1998, 34, 1522–1534

9. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002; 94(11): 3032-41.